Beijing Sungen Biomedical Technology Co., Ltd. (Sungen Biomedical) is an innovation-driven, clinical-stage biopharmaceutical company dedicated to the development of First-in-Class (FIC) and Best-in-Class (BIC) antibody-based therapeutics. Founded in 2018 and incubated by Beijing Hotgen Biotech Co., Ltd. (SH.688068), the company leverages international standard technology platforms to address critical unmet clinical needs in cardiovascular diseases, oncology, and neurodegenerative disorders.
The company is a pioneer in the field of cardiovascular immunotherapy, having developed the world's first monoclonal antibody for the emergency treatment of acute myocardial infarction (AMI). Sungen's R&D capabilities are supported by proprietary platforms, including an AI-powered drug discovery system, a next-generation 'SG Linker-Payload' platform for ADC development, and a comprehensive in-house manufacturing and quality control infrastructure located in Beijing's 'China Pharmaceutical Valley'.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:Pre-revenue
Founded:2018
Ownership:subsidiary
Status:operating
FUNDING
Stage:Series A
Total Raised:$40M
Investors:Beijing Hotgen Biotech Co., Ltd., Qingdao Chuangjing Private Equity Fund Management Co., Ltd., Tianjin Hidea Venture Capital Management Co., Ltd., Green Pine Capital Partners Co., Ltd., Fortune Venture Capital Co., Ltd.
STOCK
Exchange:SSE (Parent: SH.688068)
Ticker:688068
Market Cap:N/A
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2 (SGC001)
Modalities:Monoclonal antibody (mAb), Bispecific antibody (BsAb), Antibody-drug conjugate (ADC), Antibody-oligonucleotide conjugate (AOC)
Active Trials:2
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Beijing Hotgen Biotech Co., Ltd.
Key Partnerships:Beijing Institute of Heart, Lung and Blood Vessel Diseases (R&D collaboration), Beijing Antai Institute of Cardiovascular Medicine (Joint Laboratory), Shenzhen Zhiyuan Biomedical Co., Ltd. (Joint Laboratory), Academy of Military Medicine, Chinese Academy of Military Sciences (Research collaboration)
COMPETITION
Position:Emerging
Competitors:Bristol Myers Squibb (CTLA4 targets), AstraZeneca (Cardiovascular pipeline), Sanofi (Antibody platforms), Amgen (Cardiovascular/Oncology)
LEADERSHIP
Key Executives:
Sun Zhiwei - Co-founder & General Manager
Lin Changqing - Chairman
Zhonghai Yan - BD Director
Wei Zeng - Vice President
Scientific Founders:Professor Sun Zhiwei
Board Members:Lin Changqing
LINKS
Website:sungenbiomed.com.cn
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Beijing Sungen Biomedical Technology Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Beijing Sungen Biomedical Technology Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.